Spesolimab-Sbzo

Introduction Overview

Generic Name

spesolimab-sbzo

Brand Name

Spevigo

Dosage Form

single-dose vial for intravenous use (450 mg/7.5 mL), single-dose prefilled syringe for subcutaneous use (300 mg/2 mL, 150 mg/mL)

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption:
Spevigo (spesolimab-sbzo) is administered either intravenously or subcutaneously, depending on the indication. When used for acute generalized pustular psoriasis (GPP) flares, it is given as an intravenous infusion, leading to immediate bioavailability as the drug directly enters systemic circulation. For maintenance therapy, subcutaneous administration provides gradual absorption through the subcutaneous tissue. The bioavailability of the subcutaneous formulation is influenced by factors such as lymphatic uptake and local blood flow, but precise bioavailability percentages have not been published publicly. Clinical use indicates effective systemic exposure after both routes.

Distribution:
As a monoclonal antibody, Spevigo has a large molecular size, limiting its distribution primarily to the vascular and interstitial spaces. The volume of distribution is expected to be low to moderate, consistent with immunoglobulin G (IgG) antibodies. It does not readily cross the blood-brain barrier. Binding is specific to the interleukin-36 receptor (IL-36R), predominantly expressed in skin and immune cells implicated in psoriasis. Tissue penetration relates to inflammation status; inflamed tissues may have increased vascular permeability, enhancing local drug concentration.

Metabolism:
Monoclonal antibodies like Spevigo are predominantly catabolized by proteolytic enzymes into small peptides and amino acids through cellular uptake and lysosomal degradation. This process occurs mainly via the reticuloendothelial system and does not involve hepatic cytochrome P450 enzymes. Therefore, Spevigo metabolism is not significantly impacted by liver enzyme-mediated drug interactions, reducing the risk of hepatic metabolism-related variability or drug-drug interactions.

Elimination:
The elimination half-life of spesolimab-sbzo has not been explicitly disclosed, but monoclonal antibodies typically have half-lives ranging from days to weeks, reflecting slow proteolytic catabolism and recycling mechanisms via the neonatal Fc receptor (FcRn). Elimination occurs primarily through cellular degradation rather than renal or hepatic excretion. Immune-mediated clearance and formation of anti-drug antibodies (ADAs) could potentially impact pharmacokinetics and efficacy, although clinical data on immunogenicity and pharmacokinetic variability are limited. No detailed excretion data has been made publicly available.

Dosage Forms

Available Dosage Forms:
Spevigo is supplied in two primary formulations tailored for differing clinical uses:
- Intravenous route: single-dose vial containing 450 mg of spesolimab-sbzo per 7.5 mL solution (60 mg/mL concentration). Used specifically for acute GPP flare treatment.
- Subcutaneous route: prefilled syringes available in two strengths for maintenance therapy—300 mg/2 mL (150 mg/mL) and 150 mg/mL single-dose syringes packaged in cartons of two. This permits flexible dosing and facilitates self-administration following healthcare provider training.

Dosages for Adults and Adolescents:
- For acute GPP flares, adults and children 12 years and older weighing at least 40 kg receive 900 mg administered intravenously as a single infusion over approximately 90 minutes. If clinical response is inadequate after 1 week, a second 900 mg IV dose may be given.
- For maintenance therapy in adults and adolescents 12 years and older, the regimen includes a loading dose of 600 mg subcutaneously administered by a healthcare provider initially, followed by 300 mg subcutaneously every 4 weeks thereafter. Patients previously treated with IV Spevigo for a flare do not require the loading dose. Self-administration is possible once adequate training is provided, with injections typically delivered into the abdomen or upper thighs.

Specific Patient Populations:
- Pediatric use is limited to adolescents aged 12 and older who weigh at least 40 kg. Safety and efficacy in younger children or lower weight groups have not been established.
- Dose adjustments based on renal or hepatic impairment are not documented, consistent with monoclonal antibody pharmacokinetics.
- Injection technique, needle size, and rotation of sites should be carefully managed, particularly for pediatric and geriatric patients to minimize local reactions.
- Patients with active infections require evaluation prior to treatment initiation, given immunomodulatory effects.

Comprehensive clinical guidelines recommend adherence to dosing schedules and monitoring for infusion or injection site reactions.

Mechanism Of Action

Spevigo (spesolimab-sbzo) acts as a humanized monoclonal antibody targeting the interleukin-36 receptor (IL-36R). The IL-36 receptor is a critical mediator of inflammatory signaling pathways implicated in generalized pustular psoriasis (GPP). Spevigo selectively binds to IL-36R, preventing the binding of IL-36 cytokines (IL-36α, IL-36β, and IL-36γ), which are potent pro-inflammatory ligands involved in innate immune responses and keratinocyte activation.

By inhibiting IL-36R activation, Spevigo interrupts downstream signaling cascades, including the NF-κB and MAP kinase pathways, which lead to transcription of inflammatory mediators, recruitment of immune cells, and hyperproliferation of keratinocytes. This blockade reduces the overactive immune response characteristic of GPP, leading to a rapid reduction in pustular lesions and systemic inflammation.

Cellularly, Spevigo's inhibition of IL-36R modulates both innate immune cells, such as dendritic cells, macrophages, and neutrophils, as well as the keratinocytes responsible for skin barrier function and inflammation. This modulation restores homeostasis within skin tissue and decreases the intense inflammatory milieu underpinning GPP pathogenesis.

Clinically, this targeted approach provides an advantage over broad immunosuppressants by focusing on a critical, disease-specific pathway, resulting in rapid pustular clearance during flares and sustained remission during maintenance therapy. Compared with other interleukin inhibitors targeting IL-17, IL-23, or IL-12/23 pathways used in plaque psoriasis, Spevigo specifically addresses the IL-36 axis, underlying the unique inflammatory profile of GPP. Clinical trials such as Effisayil 1 and 2 demonstrate the efficacy and safety of this approach. Ongoing research continues to elucidate the broader immunological roles of IL-36 signaling in psoriasis and potential applications of IL-36R antagonism in other inflammatory diseases.

Pharmacological Actions

Selective blockade of the interleukin-36 receptor (IL-36R), preventing downstream inflammatory cytokine signaling.
Modulation of innate immune responses, reducing activation and recruitment of neutrophils and other inflammatory cells.
Inhibition of keratinocyte hyperproliferation and associated psoriatic skin manifestations by interrupting key inflammatory pathways.
Reduction of systemic inflammation characteristic of generalized pustular psoriasis (GPP) flares.
Immunomodulatory effects that restore balance within the skin microenvironment without broad immunosuppression.
Rapid onset of action leading to pustular lesion clearance within days of administration during acute flares.
Maintenance of disease remission by sustained suppression of IL-36 mediated pathways with periodic subcutaneous dosing.
Potential to reduce reliance on systemic corticosteroids and traditional immunosuppressants with their associated side effects.
Does not undergo hepatic metabolism, reducing risk of cytochrome P450 interactions.
Limited distribution primarily in vascular and interstitial compartments due to monoclonal antibody properties.
Clinical efficacy supported by Phase 3 trials demonstrating significant improvements in GPP disease activity scores.
Exhibits a favorable safety profile with specific monitoring recommendations to mitigate infection risks.
Minimal reported immunogenicity with continued therapy to date.
Provides a novel mechanism of action complementary to other biologic treatments for psoriasis variants.
Facilitates outpatient management of GPP with self-administered subcutaneous maintenance dosing.

Therapeutic Or Clinical Uses

Treatment of generalized pustular psoriasis (GPP) flares in adults and adolescents aged 12 years and older weighing at least 40 kg.
Maintenance therapy to prevent GPP flares and sustain remission in adults and adolescents with GPP.
Use in patients who have an inadequate response or contraindications to traditional systemic therapies.
Management of acute GPP episodes to rapidly reduce pustular lesions and systemic inflammatory symptoms.
Alternative treatment option for patients requiring targeted immunomodulation with a novel mechanism.
Potential utility in pediatric patients 12 years and older under supervised administration.
Reduction in disease-related morbidity and improvement in quality of life for patients with GPP.
Therapy designed for administration in outpatient and clinical settings with options for self-injection.
May serve as a steroid-sparing agent in GPP management to limit adverse effects of corticosteroids.
Adjunctive therapy in complex dermatological autoimmune conditions related to IL-36 pathway dysregulation.
Pharmacologic intervention aligning with recent clinical guidelines on interleukin inhibitors in dermatology.
An option for patients with recurrent flares despite optimized topical or systemic treatments.
Use authorized by FDA since 2022 based on robust clinical trial evidence.
Ongoing evaluation in research settings for broadened indications involving IL-36 mediated inflammation.
Not indicated for plaque psoriasis; specific for the pustular variant highlighting distinct pathophysiology.

Side Or Adverse Effects

Fatigue and weakness, commonly reported during GPP flare treatment.
Nausea and vomiting, especially noted after intravenous infusion.
Headache as a frequently observed neurological side effect.
Itching or pruritic skin bumps occurring both during flare treatment and maintenance.
Local injection site reactions including redness, pain, swelling, warmth, induration, and urticaria during subcutaneous administration.
Development of bruising or hematoma at infusion sites as a result of vascular fragility post-IV administration.
Urinary tract infections, observed in both acute and maintenance treatment cohorts.
Joint pain or arthralgia reported during maintenance therapy.
Potential for serious infections due to immunosuppression, including tuberculosis reactivation risk.
Infusion-related reactions manifesting as chest tightness, hives, facial swelling, dyspnea, hypotension, or fever.
Severe allergic or anaphylactic reactions necessitating immediate discontinuation.
Possible mouth sores and mucosal irritation linked to immune modulation.
Increased susceptibility to opportunistic infections, mandating close clinical surveillance.
Uncommonly reported systemic hypersensitivity reactions including swelling of eyelids, lips, or throat.
Theoretical risk of impaired vaccine response and caution indicated with live vaccines.

Precautions

Screen patients for active infections and tuberculosis prior to initiation due to immunosuppressive effects.
Evaluate patient history for recurrent infections or immunodeficiency states before starting Spevigo.
Update vaccination status prior to therapy; avoid live vaccines during treatment and for at least 16 weeks post-therapy.
Monitor patients closely for signs and symptoms of infection throughout therapy and promptly treat if infection occurs.
Exercise caution in patients with compromised immune systems or concomitant use of other immunosuppressive agents.
Advise patients regarding potential infusion or injection site reactions and management strategies.
Ensure patients understand administration technique and importance of adherence to dosing schedules for maintenance therapy.
Use caution in pregnant or breastfeeding women; risk to fetus or infant is unknown and should be weighed against potential benefit.
Pediatric patients aged 12–17 should only self-administer under adult supervision.
Patients should inform healthcare providers of all medications, supplements, and herbal products due to potential immune interactions.
Discontinue or delay treatment if serious allergic or infusion-related reactions occur.
Avoid abrupt discontinuation without physician guidance, especially during flare episodes.
Provide thorough patient education concerning signs of hypersensitivity or infection requiring urgent evaluation.
Store prefilled syringes refrigerated; protect from freezing and direct sunlight to maintain drug integrity.
Regularly reassess risk-benefit profile and monitor for development of anti-drug antibodies that may affect efficacy.

Warnings

Risk of serious infections including tuberculosis, bacterial, fungal, or viral infections due to immunomodulation.
Serious allergic and infusion-related reactions can occur, including anaphylaxis, requiring immediate medical intervention.
Do not administer live vaccines concomitantly with Spevigo or within 16 weeks after treatment completion.
Potential for immune system compromise; monitor closely for febrile episodes, cough, dyspnea, and other infection symptoms.
Spevigo is not established as safe or effective in children under 12 years or those weighing less than 40 kg.
Pregnancy safety has not been established; fetal risk remains unknown—use only if clearly needed and after risk assessment.
Breastfeeding safety is unknown; consider discontinuing nursing or drug depending on clinical judgment.
Do not use Spevigo in patients with known severe hypersensitivity to spesolimab or any formulation components.
Adverse events from infusion reactions may necessitate therapy interruption or discontinuation.
Careful monitoring is advised in patients with comorbid conditions that may predispose to infections.
Patients should be informed to immediately report symptoms of infection or allergic reactions during and after therapy.
There is limited long-term safety data available; continued pharmacovigilance is essential.
Avoid abrupt cessation during a GPP flare; coordinate transition with healthcare provider to prevent worsening.
Spevigo may diminish immunologic response to vaccines; immunization schedules should be adapted accordingly.
Use with caution in combination with other potent immunosuppressants due to additive risks.

Contraindication

Known hypersensitivity to spesolimab-sbzo or any inactive ingredient in Spevigo formulations.
History of severe or life-threatening allergic reactions to Spevigo or related interleukin inhibitors.
Active, untreated tuberculosis or other serious systemic infections.
Concurrent administration with live vaccines due to risk of uncontrolled infection.
Patients with a history of severe infusion-related reactions to biologic therapies unless under strict medical supervision.
Use in pediatric patients under 12 years of age or under 40 kg body weight due to lack of safety and efficacy data.
Known immunodeficiency disorders or ongoing immunosuppressive conditions without adequate infection control.
Use during pregnancy unless potential benefits justify potential risks to the fetus.
Patients with hypersensitivity to any excipients such as polysorbate 20 or sucrose.
Previous severe hypersensitivity to any monoclonal antibody treatment unless alternative treatments are unavailable.
Patients with unresolved infections despite standard therapies.
Use contraindicated when immediate treatment with live vaccines is required.
Severe hepatic impairment has not been studied; cautious use advised though not formally contraindicated.
Concurrent participation in other investigational drug trials without appropriate washout.
Contraindicated in individuals with unstable or heavily immunocompromised conditions without specialist oversight.

Drug Interactions

Potential interaction with other immunosuppressive therapies leading to enhanced immunosuppression and increased risk of infection.
Reduced efficacy or increased adverse effects if administered concomitantly with TNF inhibitors such as infliximab due to overlapping mechanisms.
Increased susceptibility to infections when combined with other biologics targeting immune pathways.
Contraindicated or should be avoided with live attenuated vaccines due to impaired vaccine response and infection risk.
Certain herbal supplements and probiotics may modulate immune response and could theoretically alter Spevigo's effects; monitor accordingly.
Lack of cytochrome P450 metabolism decreases risk of classic drug interactions involving hepatic enzymes.
No formal drug interaction studies have been completed; clinical vigilance during polypharmacy is warranted.
Potential for interference with immune-based diagnostic tests such as tuberculin skin test or interferon-gamma release assays.
Co-administration with corticosteroids may augment immunosuppressive effects but may be necessary in acute management.
Interactions with antiviral or antibacterial agents are not established but caution advised in managing infections.
Drugs affecting lymphatic or immune cell trafficking could theoretically alter pharmacodynamics.
No known pharmacokinetic interactions affecting absorption or elimination parameters.
Monitoring recommended if patients receive vaccines requiring robust immune responses to ensure efficacy.
Patients should disclose all supplements and prescription medications prior to initiating Spevigo therapy.
Clinicians should consider immunization planning before and after Spevigo therapy to mitigate infection risk.

Preparations Of The Drug

Single-dose vial for intravenous infusion: 450 mg spesolimab-sbzo in 7.5 mL solution (60 mg/mL concentration) designed for IV administration over 90 minutes.
Single-dose prefilled syringe for subcutaneous injection: 300 mg in 2 mL solution (150 mg/mL) intended for maintenance therapy dosing.
Single-dose prefilled syringe for subcutaneous injection: 150 mg/mL formulation available in cartons containing two syringes for flexible dosing.
Inactive ingredients include arginine hydrochloride, glacial acetic acid, polysorbate 20, sodium acetate, sucrose, and Water for Injection, ensuring solution stability and biocompatibility.
Prefilled syringes must be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light; do not freeze as this compromises integrity.
Before subcutaneous administration, syringes should be allowed to warm to room temperature for 15 to 30 minutes without exposure to direct sunlight or heat sources.
Intravenous vials require dilution prior to infusion as per prescribing information to achieve appropriate concentration and volume for infusion.
Each carton of prefilled syringes contains two single-dose units with clear labeling to ensure correct identification and dosing.
The formulation is preservative-free and indicated for single use to avoid contamination and maintain sterility.
Prefilled syringes enable patient self-administration following adequate healthcare provider training, promoting adherence and convenience.
Packaging includes tamper-evident seals and detailed administration instructions compliant with regulatory standards.
Manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., adhering to stringent quality control and Good Manufacturing Practices (GMP).
The preparation's excipients support antibody stability and minimize local injection site reactions.
No generic or biosimilar equivalents currently available, ensuring formulation consistency and controlled distribution.
Comprehensive prescribing information available to healthcare professionals detailing reconstitution, storage, administration, and disposal procedures.